Scarica l'app Stockscreener
3.35
4.04%
0.13
Dopo l'orario di chiusura:
3.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.22
Aprire:
$3.17
Volume 24 ore:
548.38K
Relative Volume:
1.52
Capitalizzazione di mercato:
$128.36M
Reddito:
$1.50M
Utile/perdita netta:
$-81.41M
Rapporto P/E:
-0.695
EPS:
-4.82
Flusso di cassa netto:
$-43.75M
1 W Prestazione:
+13.56%
1M Prestazione:
+20.07%
6M Prestazione:
+83.06%
1 anno Prestazione:
-25.22%
Intervallo 1D:
$3.13
$3.36
Intervallo di 1 settimana:
$2.72
$3.36
Portata 52W:
$1.68
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Nome
Leap Therapeutics Inc
Settore
Industria
Telefono
617 252 4343
Indirizzo
47 THORNDIKE STREET, CAMBRIDGE, MA
Confronta LPTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
3.35 | 128.36M | 1.50M | -81.41M | -43.75M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-10-04 | Iniziato | Mizuho | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2019-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | Ripresa | Raymond James | Outperform |
| 2017-03-07 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Leap Therapeutics Inc Borsa (LPTX) Ultime notizie
Gastric Cancer Pipeline, Treatment Drugs, Clinical Trials and Companies 2024 (Updated) - openPR
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Up 50.7% in December - MarketBeat
HighTower Advisors LLC Makes New $65,000 Investment in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch
Biliary Tract Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Neural Therapeutics Announces Changes to Board of Directors and Completion of Debt Settlement - Yahoo Finance
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap - Investing.com Australia
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap By Investing.com - Investing.com South Africa
LEAP-012 Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma - The ASCO Post
Leap Therapeutics CEO to Present at Piper Sandler Healthcare Conference | LPTX Stock News - StockTitan
HC Wainwright Reaffirms Buy Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
Microsoft's Azure Chips Promise AI Leap, Taking on Nvidia and AMD in Cloud Tech Race - Yahoo Finance
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Balyasny Asset Management L.P. Reduces Stake in Leap Therapeutics Inc - GuruFocus.com
Leap Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Leap Therapeutics Reports Wider Q3 Loss, Advances Cancer Drug Trials with $62.8M Cash | LPTX Stock News - StockTitan
Liquor, Wine, Beer: Which Comes With the Worst Lifestyle? - 69News WFMZ-TV
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, - GlobeNewswire
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Payment processor Finix secures $75m in Series C funding - Electronic Payments International
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases - Business Wire
FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug - pharmaphorum
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma
Dow Jones notches new record, chip stocks leap higher - Yahoo Finance
Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC) - Defense World
Profire Energy, Inc. (NASDAQ:PFIE) Shares Sold by Marshall Wace LLP - Defense World
Marshall Wace LLP Makes New Investment in Vivid Seats Inc. (NASDAQ:SEAT) - Defense World
SoFi's $2 Billion Leap: Golden Cross Sparks A Bullish Boom - Yahoo Finance
Startup company founded by Washington University scientists acquired by Eli Lilly – WashU Medicine - WashU Medicine
Venous Leg Ulcers Treatment Market value, Innovations Driving Market Evolution (2024-2036) - Third Eye News
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - The Malaysian Reserve
LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India
Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Alphamin Resources Corp. (CVE:AFM) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World
Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World
Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Leap Therapeutics Inc Azioni (LPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):